A promoter-associated RNA downregulates the oncogenic GLI1 transcription factor in rhabdomyosarcoma cells by Peter G Zaphiropoulos
RNA & DISEASE 2014; 1: e254. doi: 10.14800/rd.254; ©  2014 by Peter G. Zaphiropoulos. 
http://www.smartscitech.com/index.php/rd 
Page 1 of 3 
A promoter-associated RNA downregulates the oncogenic 
GLI1 transcription factor in rhabdomyosarcoma cells 
Peter G. Zaphiropoulos
Department of Biosciences and Nutrition Karolinska Institutet, 14183 Huddinge, Sweden
Correspondence: Peter G. Zaphiropoulos 
E-mail: peter.zaphiropoulos@ki.se
Received: July 21, 2014
Published: December 25, 2014
Recent experimental evidence demonstrates a novel regulatory mechanism on the expression of the GLI1 
oncogene, a transcriptional effector of Hedgehog signaling. This is mediated by a non-coding RNA, antisense to 
the GLI1 promoter, GLI1AS, which elicits negative feedback on GLI1 expression. Knockdown of GLI1AS was 
shown to enhance rhabdomyosarcoma tumor growth in a xenograft model, in-line with the observed increase of 
the expression levels of GLI1, a known proliferative/oncogenic factor in this cellular context. 
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GLI1 and oncogenic signaling 
Glioma-associated oncogene 1 (GLI1) is a terminal 
effector of Hedgehog signaling that acts to further enhance 
transcriptional activation, initially elicited by its homologs 
GLI2 and GLI3. GLI1 is a five-zinc finger protein that is 
upregulated by Hedgehog signaling and serves as a marker of 
pathway activity. Among GLI1 targets is GLI1 itself and this 
generates a positive feedback loop in GLI1 activation 
[1, 2]
.
GLI1 is an oncogene and overexpression of GLI1 was 
shown to result in basal cell carcinoma-like lesions in 
transgenic mice 
[3]
. On the other hand inactivation of GLI1
has no visible phenotype in mice, however in combination 
with a GLI2 knockout, more pronounced developmental 
defects are observed 
[4]
. Moreover, a recent detailed analysis
demonstrated the impact of this GLI1 inactivation in 
embryonic thymocyte differentiation 
[5]
. Additionally, GLI1
knockdown or small molecule inhibition of GLI1 activity 
reduces rhabdomyosarcoma cell proliferation and tumor 
growth in a xenograft model 
[6]
. Similar results, highlighting
the oncogenic properties of GLI1, were also observed with 




Recent global analysis has shown that gene promoters 
generate transcripts not only in the direction of the 
protein-encoding gene, but also in the opposite orientation 
(antisense transcription). These antisense transcripts, termed 
promoter-associated RNAs, are generally considered to be 
short and unstable, bearing similarities with 
enhancer-associated transcripts, with little evidence for 
functionality 
[8]
. However, accumulated recent data
indicating that certain promoter-associated RNAs may be 
longer multi-exon RNAs with defined biological roles are 
starting to emerge 
[9-11]
.
GLI1AS, a functional antisense RNA from the GLI1 
promoter 
Bioinformatic and experimental analysis has demonstrated 
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that a three-exon non-coding RNA from the antisense strand 
of the GLI1 gene, flanking the GLI1 promoter, which we 
termed GLI1 antisense (GLI1AS), is expressed in a variety of 
human cell lines and tumor samples. Moreover, GLI1AS 
expression was found to correlate well to that of GLI1, with 
GLI1AS being a target gene of the GLI1 transcription factor. 
Interestingly, siRNA depletion of GLI1AS or GLI1AS 
overexpression in rhabdomyosarcoma cells resulted in 
changes of GLI1 mRNA, an increase and a decrease, 
respectively. These modulations of the GLI1AS RNA levels, 
with the concomitant changes in GLI1 expression, had an 
impact in rhabdomyosarcoma cell proliferation and tumor 
growth in xenografts on fertilized chicken egg 
(chorioallantoic membrane CAM assay) 
[12]
. Consequently, 
the accumulated evidence suggests that GLI1 and GLI1AS 
are co-regulated, with GLI1AS down regulating the 
expression of the GLI1 oncogene, acting therefore as a tumor 
suppressor gene in rhabdomyosarcoma (Figure 1)  
Future directions 
There are several important questions that should be 
addressed to further unravel the biological implications of 
GLI1AS. 
1. GLI1AS clearly regulates GLI1 in rhabdomyosarcoma 
cells and GLI1 is a proliferative/oncogenic factor in these 
tumor cells. However, it is possible that GLI1AS may affect 
the expression of other genes as well. Consequently, global 
analysis to identify possible additional targets of GLI1AS is 
a priority. 
2. GLI1AS appears to act as an epigenetic modulator 
eliciting repressive chromatin marks at the GLI1/GLI1AS 
locus, with the polycomb complex apparently involved. This 
has to be demonstrated by RNA immunoprecipitation 
analysis. Additionally, cellular factors that may interact with 
GLI1AS should be identified in unbiased approaches. 
3. A structure/function analysis of GLI1AS is highly 
relevant, as very little is known about functional domains in 
non-coding RNAs. This may also address whether known 
polymorphisms in GLI1AS could affect its capacity to act as 
a tumor suppressor. 
4. Examining the role of GLI1AS in additional cellular 
contexts, especially in other GLI1-dependent cancers, 
including neuroblastoma, medulloblastoma, breast and 
pancreatic cancer, is highly relevant.  
5. The possibility of exploiting alterations in the 
GLI1AS/GLI1 expression ratio for cancer therapeutic 
approaches should be considered. 
Conclusion 
A three-exon non-coding RNA from the antisense strand 
of the GLI1 oncogene is not only co-regulated with GLI1 but 
also represses GLI1 expression, acting therefore as a tumor 
suppressor gene.  
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Figure 1. Pathway signals (green lighting) that upregulate 
GLI1 also upregulate GLI1AS as the same promoter is used 
(bi-directional transcription). GLI1, acting as a transcription 
factor, upregulates GLI1AS expression (green arrow), which in turn 
downregulates GLI1 expression (red arrow) through epigenetic 
modification. Thus, a GLI1-GLI1AS regulatory loop is established. 
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